Joint Panel Composition and Selection Sample Clauses

Joint Panel Composition and Selection a. The Joint Panel shall be made up of four classroom teachers elected by teachers; one from kindergarten, one from grades 1-3, one from grades 4-6, and one from grades 7-8, in secret ballot elections conducted by the Association and three administrators, at least one being a site administrator, appointed by the District. b. Open nominations for classroom teacher representatives on the Joint Panel shall take place between April 1 and April 15 of each year vacancies occur. c. A quorum of the joint panel consists of at least 2 administrative members and 3 teacher members. d. The election of Joint Panel members shall take place on or before April 30 of each year vacancies occur. If not enough teachers apply for the Joint Panel positions, or a teacher position becomes vacant during the term, the Association may appoint teachers to the open positions. e. A Joint Panel year is defined as July 1- June 30. f. Each teacher elected to the Joint Panel shall serve a term of not more than two years and may succeed himself/herself only once without a break in term unless seeking reelection unopposed. For the first year those serving shall randomly be selected for a one or two year term. Two of the three administrative representatives shall serve no more than four years without a break.
Sample 1Sample 2Sample 3
AutoNDA by SimpleDocs
Joint Panel Composition and Selection. 19.6.1 The PAR program is supervised and evaluated by a Joint Panel composed of a majority of certificated classroom teachers chosen to serve by other certificated classroom teachers and administrators chosen to serve by the district, as follows: two administrators selected by the superintendent and three teachers selected by the Association. The chair will be chosen annually by the Joint Panel. A Panel year is defined as July 1 - June 30. A Panel Member's term shall be no more than three years. For the first year, those selected shall be randomly appointed for two or three year terms.
Sample 1Sample 2
Joint Panel Composition and Selection. The PAR program is supervised and evaluated by a Joint Panel composed of a majority of certificated classroom teachers chosen to serve by other certificated classroom teachers chosen to serve by other certificated classroom teachers and administrators chosen to serve by the District, as follows: three administrators selected by the superintendent and four teachers selected by the association. A panel year is defined as July 1 – June 30. A Panel Member’s term shall be no more than three years. Panel Members must be off the panel for at least one year before being re-selected. For the first year, those selected shall be randomly appointed for two or three year terms. The Panel shall select a chairperson each year. The panel shall invite the District Director of Teacher Support Services in on discussions regarding all coordination of the PAR Program with the BTSA Program.
Sample 1
Joint Panel Composition and Selection. The PAR program is supervised and evaluated by a Joint Panel composed of a majority of certificated classroom teachers chosen to serve by other certificated classroom teachers and administrators chosen to serve by the district, as follows: three administrators selected by the superintendents and four teachers selected by the associations, representing six small districts. Districts shall draw lots for representation by their association or their administration. By lot, one of the six districts will select both a teacher and an administrator. The chair alternates annually between a teacher and an administrator. A Panel year is defined as July 1 - June 30. A Panel Member's term shall be no more than three years. Panel Members must be off the pane l for at least one year before being reselected. For the first year, those selected shall be randomly appointed for two or three year terms.
Sample 1
Joint Panel Composition and Selection. The PAR program is supervised and evaluated by a Joint Panel composed of a majority of certificated classroom teachers chosen to serve by other certificated classroom teachers and administrators chosen to serve by the District, as follows: three administrators selected by the superintendent and four teachers selected by the Association, to include a representative from elementary, middle, and high school levels, and the president or designee. The chair alternates annually between a teacher and an administrator. A Panel year is defined as July 1 - June 30. A Panel Member’s term shall be no more than three years. Panel Members must be off the panel for at least one year before being re-selected. For the first year, those selected shall be randomly appointed for two or three year terms.
Sample 1
Joint Panel Composition and Selection. 19.6.1 The PAR program is supervised and evaluated by a Joint Panel composed of a majority of certificated classroom teachers chosen to serve by other certificated classroom teachers and administrators chosen to serve by the district, as follows: two administrators selected by the Superintendent and three teachers selected by the Association. The chair will be chosen annually by the Joint Panel.
Sample 1
Joint Panel Composition and Selection. The PAR program is supervised 16 and evaluated by a Joint Panel. The JP shall consist of five (5) members, 17 the majority of whom shall be permanent certificated classroom teachers 18 chosen by HTA. HTA shall appoint three (3) teachers to the JP. The 19 District shall appoint two (2) administrators to the JP. The District and 20 HTA shall each appoint one (1) alternate to serve in the event of an 21 absence of a regularly appointed member. The Chair alternates annually 22 between a teacher and an administrator. A panel year is defined as July1 23 through June 30. The Panel members’ term shall be no more than three (3) 24 years. Panel members must be off the panel for at least one (1) year before 25 being re-selected. For the first year, one (1) teacher and one administrator 26 shall be appointed for a one (1) year term; one (1) teacher and one (1)
Sample 1
AutoNDA by SimpleDocs
Joint Panel Composition and Selection a. The PAR Joint Panel consists of four classroom teachers appointed by the Association and three administrators, at least one being a site administrator, appointed by the District. b. Consists of four classroom teachers made up of at least one of each of the following: lower elementary, upper elementary and junior high. c. Appointment of Joint Panel classroom teacher representatives shall be submitted to Human Resources by May 30 of each year vacancies occur. d. A quorum of the joint panel consists of at least 2 administrative members and 3 teacher members. e. A Joint Panel year is defined as July 1- June 30. f. Each teacher appointed to the Joint Panel shall serve a term of not more than two years and may succeed themselves only once without a break in term. For the first year those serving shall randomly be selected for a one or two year term. Two of the three administrative representatives shall serve no more than two consecutive two year terms.
Sample 1

Related to Joint Panel Composition and Selection

  • Formation and Composition The Parties to this agreement will maintain a Joint Administration and Dispute Resolution Committee (JADRC) consisting of five (5) representatives of the employers and five (5) representatives of the Provincial Bargaining Council.

  • Committee Composition The Redeployment Committee shall be comprised of equal numbers of representatives of the Hospital and of the Union. The number of representatives will be determined locally. Where for the purposes of HTAP (the Ontario Hospital Training and Adjustment Panel) there is another hospital-wide staffing and redeployment committee created or in existence, Union members of the Redeployment Committee shall serve on any such hospital-wide staffing committee established with the same or similar terms of reference, and the number of Union members on such committee will be proportionate to the number of its bargaining unit members at the particular Hospital in relation to other staff groups. Meetings of the Redeployment Committee shall be held during normal working hours. Time spent attending such meetings shall be deemed to be work time for which the representative(s) shall be paid by the Hospital at his or her regular or premium rate as may be applicable. Each party shall appoint a co-chair for the Redeployment Committee. Co-chairs shall chair alternative meetings of the Committee and will be jointly responsible for establishing the agenda of the Committee meetings, preparing minutes and writing such correspondence as the Committee may direct.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be submitted to the U.S. Food and Drug Administration (the “FDA”) or other comparable government entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies and trials; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes reasonably call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or written correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Vaccination and Inoculation ‌ (a) The Employer agrees to take all reasonable precautions to limit the spread of infectious diseases among employees, including in-service seminars for employees. Where the Employer or Occupational Health and Safety Committee identifies high risk areas which expose employees to infectious or communicable diseases for which there are protective immunizations available, such immunizations shall be provided at no cost to the employee. The Committee may consult with the Medical Health Officer. Where the Medical Health Officer identifies such a risk, the immunization shall also be provided at no cost. The Employer shall provide Hepatitis B vaccine, free of charge, to those employees who may be exposed to bodily fluids or other sources of infection. (b) An employee may be required by the Employer, at the request of and at the expense of the Employer, to take a medical examination by a physician of the employee's choice. Employees may be required to take skin tests, x-ray examination, vaccination, and other immunization (with the exception of a rubella vaccination when the employee is of the opinion that a pregnancy is possible), unless the employee's physician has advised in writing that such a procedure may have an adverse effect on the employee's health.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular: (a) review and recommend the Commercialization Plans and related activities with respect to the Commercialization of Products in the Collaborator Territory, and report to the JEC on all significant Commercialization activities in the Collaborator Territory; (b) provide a forum for and facilitate communications and coordination between the Parties with respect to the Commercialization of Products in the Collaborator Territory and the Exelixis Territory; (c) on an annual basis, discuss and establish Collaborator’s Minimum Commercial Performance thresholds pursuant to Section 6.3(b) and propose recommendation to JEC; [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. (d) review the status of material Product manufacturing and supply activities and strategies associated with Commercialization; (e) review and discuss the major findings of Collaborator’s market research with respect to any Product in the Collaborator Territory, if any; (f) review and oversee the branding and product positioning strategy for Products in the Collaborator Territory and evaluate Collaborator’s brand strategy for the Product in the Collaborator Territory for consistency with the then-current global brand strategy for the Product; (g) discuss Product list price and status of reimbursement in the Collaborator Territory; and (h) perform such other functions as may be appropriate to further the purposes of this Agreement with respect to the Commercialization of Products, including endeavoring to resolve any disputes between the Parties arising from the deliberations of the JCC, or as otherwise directed by the JEC.

  • Composition of Committee A Union/Management Committee shall be established. The Employer and the Union shall each appoint two (2) representatives to the Union/Management Committee.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Commercialization Plan (a) Not later than three [***] after submission of Regulatory Filings for each Product in each country of the Territory, Licensee will provide to the JCC for review its initial Commercialization Plan for each Product for each country in the Territory. Such initial Commercialization Plan will describe Licensee’s plans for activities to be conducted for such Product for such country. Each Commercialization Plan shall include the details of obligations to be performed by Licensee to achieve the specific activities that are applicable to the stage of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Commercialization (e.g., pre-launch, launch planning, launch, or post-launch) of the applicable Product during the time period covered by such Commercialization Plan and subsequent time periods. (b) Prior to the First Commercial Sale for such Product in such country, Licensee will provide to the JCC for review an updated Commercialization Plan for such Product for such country. Such updated Commercialization Plan will include, but not be limited to, Licensee’s updated plans for activities to be conducted for such Product for such country prior to launch as well as activities to be conducted in connection with such launch. (c) Promptly after each anniversary of the First Commercial Sale of such Product during the Term, Licensee will provide to the JCC for review updated Commercialization Plans for such Product for such country. Such further updated Commercialization Plan will include, but not be limited to, Licensee’s plans for Commercialization activities for such Product and such country for the twelve (12) month period following the date of delivery of such Commercialization Plan. No Commercialization Plan may be implemented by Licensee if [***]. Each Commercialization Plan shall be consistent with and shall not contradict the terms of this Agreement [***], and in the event of any inconsistency between the Commercialization Plan and this Agreement, the terms of this Agreement shall prevail. Notwithstanding the foregoing, if a [***], Licensee shall [***] and shall promptly [***].

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!